Screener Summaries Updates Institutions Sign In More Updates › Other Events › NGNE Other Events · Jun 8, 2026
Neurogene completes dosing in Embolden registrational trial of NGN-401 for Rett syndrome NGNE Neurogene Inc.
Neurogene Inc. announced the completion of dosing in its Embolden TM registrational trial of NGN-401 for the treatment of Rett syndrome on June 8, 2026. The company also updated its corporate presentation on its website.
All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
